Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of subcutaneous lunsekimig in adults with asthma from DRI16762 or ACT18301
jRCT2061240137Recruiting
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of lunsekimig in asthma, sponsored by Sanofi. Primary endpoint: Treatment-emergent adverse events including AESI and SAEs. Started May 2025; status: recruiting.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2061240137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240137.